Vyvgart (efgartigamod) rapidly eased symptoms of generalized myasthenia gravis (gMG) and prevented complications before, during, and after surgery in a 23-year-old woman, a case study reported. The woman required surgery to remove a mass in her abdominal cavity while also experiencing a gMG flare-up. Clinicians successfully removed the…
News
Rystiggo (rozanolixizumab-noli) can be safely self-administered by people with myasthenia gravis (MG), according to data from a Phase 3 clinical trial. Based on these findings, at-home administration of Rystiggo was authorized earlier in 2025 in Japan and Europe. The work was funded by UCB, the company that sells Rystiggo.
Anxiety related to COVID-19 is more prevalent among people with myasthenia gravis (MG) than among the general population, a study in Germany shows. For individuals with MG, the most pronounced cause of such anxiety was the fear patients experienced about the consequences of a COVID-19 infection on their health.
People with myasthenia gravis (MG) have higher levels of a protein called neurofilament light chain (NfL) in their blood, especially if their symptoms are severe or start later in life, a recent study found. This means that NfL could help doctors track how the disease develops and decide on…
Neurologists consider the degree of clinical efficacy and the onset of action as the most important factors when making treatment decisions for their patients with generalized myasthenia gravis (gMG), according to a study. Still, there is variability, with some physicians considering the mode of treatment administration a more important…
A live, virtual panel at 6 p.m. EST on Oct. 23 will explore how people with myasthenia gravis (MG) can make lifestyle changes to reduce flares, have a more supportive relationship with their healthcare team, and find reliable information about the neuromuscular disorder. The free webinar, “Pushing Back…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CNP-106, an experimental treatment that Cour Pharmaceuticals is developing to reprogram the immune system in generalized myasthenia gravis (gMG). “Receiving orphan drug designation for CNP-106 is an important development and regulatory milestone for our…
Measuring changes in blood levels of two proteins — neurofilament light chain (NfL) and calprotectin (CLP) — may show how well people with generalized myasthenia gravis (gMG) respond to Ultomiris (ravulizumab) and Vyvgart (efgartigimod). That’s according to a small, real-world study in Germany that found that rising…
Black patients with generalized myasthenia gravis (gMG) face significantly higher risks of exacerbations compared with their white counterparts, according to a retrospective analysis of healthcare insurance claims from a U.S. database. Exacerbations refer to the worsening of existing symptoms or the appearance of new ones. “Interventions aimed at addressing…
A European Medicines Agency (EMA) committee recommended that the agency approve nipocalimab as an add-on treatment for generalized myasthenia gravis (gMG) patients aged 12 and older who have antibodies against acetylcholine receptor (AChR) or muscle-specific kinase (MuSK). The Committee for Medicinal Products for Human Use (CHMP) recommendation comes a…
Recent Posts
- Thymus gland removal seen as effective option for late-onset MG
- A caregiver’s perspective on his wife’s health after breast reduction
- My twin loves junk food, but a veggie and fruit diet is helping him combat MG
- My secret book of survival in life with myasthenia gravis
- MG symptoms in US strike earlier and harder depending on race and ethnicity